The HDL therapy was discovered at the Montreal Heart Institute Research Centre in Canada.
Cerenis Therapeutics in-licensed intellectual property related to a HDL-based treatment for aortic valve stenosis (AVS). This technology is based on the findings of a study led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre in Canada.
In Dr. Tardif’s placebo-controlled study in rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification.
“Currently, patients who suffer from severe AVS have no option other than surgical valve replacement,” according to Jean-Louis Dasseux, Ph.D., president and CEO of Cerenis. “Even after newer, minimally invasive surgery, there are risks of valve wear and blood clots, requiring permanent treatment with blood thinners.”